Barclays PLC Apellis Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 255,897 shares of APLS stock, worth $8.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

255,897

Previous 255,897 -0.0%

Holding current value

$8.48 Million

Previous $7.38 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$28.84 - $41.15 $1.13 Million - $1.61 Million	39,019 Added 17.99%	255,897 $7.38 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $7.27 Million - $11.4 Million	191,086 Added 740.87%	216,878 $8.32 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $9.45 Million - $12.4 Million	-170,599 Reduced 86.87%	25,792 $1.52 Million
Q4 2023 Feb 15, 2024	SELL	$37.14 - $64.82 $5.44 Million - $9.5 Million	-146,498 Reduced 42.72%	196,391 $11.8 Million
Q3 2023 Nov 07, 2023	BUY	$23.65 - $89.22 $725,085 - $2.74 Million	30,659 Added 9.82%	342,889 $13 Million
Q2 2023 Aug 03, 2023	BUY	$76.68 - $93.31 $5.37 Million - $6.54 Million	70,049 Added 28.92%	312,230 $28.4 Million
Q1 2023 May 04, 2023	BUY	$46.59 - $66.96 $691,116 - $993,284	14,834 Added 6.52%	242,181 $16 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $4.07 Million - $5.75 Million	94,198 Added 70.75%	227,347 $11.8 Million
Q3 2022 Nov 03, 2022	BUY	$44.76 - $69.66 $4.91 Million - $7.64 Million	109,713 Added 468.14%	133,149 $9.1 Million
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $1.02 Million - $1.73 Million	-29,168 Reduced 55.45%	23,436 $1.06 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $3.29 Million - $5.01 Million	-92,644 Reduced 63.78%	52,604 $2.67 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $3.46 Million - $5.53 Million	112,555 Added 344.28%	145,248 $6.87 Million
Q3 2021 Nov 09, 2021	SELL	$31.4 - $69.84 $138,976 - $309,111	-4,426 Reduced 11.92%	32,693 $1.08 Million
Q2 2021 Aug 13, 2021	SELL	$40.9 - $64.9 $2.25 Million - $3.56 Million	-54,915 Reduced 59.67%	37,119 $2.35 Million
Q1 2021 May 13, 2021	BUY	$40.8 - $57.39 $138,883 - $195,355	3,404 Added 3.84%	92,034 $3.95 Million
Q4 2020 Feb 11, 2021	SELL	$30.79 - $57.2 $2.22 Million - $4.13 Million	-72,188 Reduced 44.89%	88,630 $5.07 Million
Q3 2020 Nov 12, 2020	BUY	$25.89 - $33.65 $2.52 Million - $3.27 Million	97,314 Added 153.24%	160,818 $4.85 Million
Q2 2020 Aug 12, 2020	SELL	$24.8 - $38.49 $3.14 Million - $4.87 Million	-126,534 Reduced 66.58%	63,504 $2.07 Million
Q1 2020 May 13, 2020	SELL	$17.91 - $44.33 $17.4 Million - $43 Million	-970,396 Reduced 83.62%	190,038 $5.09 Million
Q4 2019 Feb 10, 2020	BUY	$22.1 - $30.8 $24.6 Million - $34.3 Million	1,113,185 Added 2356.0%	1,160,434 $35.5 Million
Q3 2019 Nov 14, 2019	SELL	$24.09 - $32.18 $1.73 Million - $2.31 Million	-71,889 Reduced 60.34%	47,249 $1.14 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $719,694 - $1.01 Million	39,983 Added 50.51%	119,138 $3.02 Million
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $993,722 - $1.54 Million	77,574 Added 4906.64%	79,155 $1.54 Million
Q4 2018 Feb 14, 2019	SELL	$11.47 - $18.71 $143,065 - $233,369	-12,473 Reduced 88.75%	1,581 $21,000
Q3 2018 Nov 14, 2018	BUY	$16.57 - $21.03 $188,997 - $239,868	11,406 Added 430.74%	14,054 $251,000
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $5,516 - $8,430	281 Added 11.87%	2,648 $58,000
Q1 2018 May 15, 2018	BUY	$14.01 - $26.02 $9,106 - $16,913	650 Added 37.86%	2,367 $53,000
Q4 2017 Feb 14, 2018	BUY	$12.71 - $21.7 $21,823 - $37,258	1,717	1,717 $37,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account